Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Prednisolone, Rituximab, Vincristine in patients with Follicular Lymphoma.
Health Canada approved rituximab for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy.
This statement is based on a regulatory approval from the Health Canada:
RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |